Anti-Rheumatic Drugs - Italy

Italy

Italy is projected to witness a notable revenue growth in the Anti-Rheumatic Drugs market.
In 2024, the revenue is estimated to reach €0.40bn.
Moving forward, the market is expected to display a steady annual growth rate (CAGR 2024-2029) of 0.00%.
This growth trajectory will lead to a market volume of €0.40bn by 2029.
When comparing in Italy to other countries on a global scale, it is important to note that United States is anticipated to generate the highest revenue in the Anti-Rheumatic Drugs market.
In 2024, United States is projected to reach a revenue of €31,850.00m.
Italy's pharmaceutical market is experiencing a surge in demand for innovative anti-rheumatic drugs, driven by the country's aging population and increased awareness of the disease.

Key regions: Germany, United States, India, Japan, United Kingdom

Mercado

Región

Comparación de regiones

Moneda

Analyst Opinion

The Anti-Rheumatic Drugs market in Italy has been steadily growing over the past few years.

Customer preferences: Patients suffering from rheumatoid arthritis and other autoimmune disorders are the primary customers of Anti-Rheumatic Drugs. These patients seek drugs that can help alleviate their symptoms and improve their quality of life. Italian customers tend to prefer drugs that are effective in managing their symptoms while also having minimal side effects.

Trends in the market: In recent years, there has been a growing trend towards the use of biologic drugs in the treatment of rheumatoid arthritis and other autoimmune disorders. These drugs are designed to target specific components of the immune system, which can help reduce inflammation and prevent joint damage. Biologic drugs have become increasingly popular in Italy due to their effectiveness and relatively low side effect profile.

Local special circumstances: One of the unique features of the Italian market is the high level of government regulation. The government plays an active role in determining which drugs are approved for use and how they are priced. This has led to a more stable and predictable market, but it can also make it difficult for new drugs to enter the market.

Underlying macroeconomic factors: The Italian economy has been relatively stable in recent years, which has helped to support growth in the Anti-Rheumatic Drugs market. However, there are concerns about the long-term sustainability of the Italian economy, particularly given the country's high levels of debt and political instability. These factors could potentially impact the growth of the Anti-Rheumatic Drugs market in the future.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.